ca_fisherman, it certainly seems like people are in waiting mode until the FDA issues its decision on Relistor label expansion. We won't have long to wait.
As I said, irrational short term market movements today. Both NKTR and PGNX were down around 3% today, but PGNX's partner SLXP was up again today.
Both PGNX and NKTR are down in the past 5 days, with NKTR down more. If there were any logic in the markets, one of them or both of them would be up.
inneedofmanythings, Wow, that wasn't an aberration. You really are ill-versed in grammar AND reading comprehension. I gave you accurate information and you follow with an absurd and delusional comment. I took a look at some of your recent posts, and it is clear you are a nasty little cur. In dealing with someone of your ilk, the best move is to ignore the ignorant. That would be you. So long you sad little loser.
telecominvest, this jmelink clown is a pathetic little troll and board regulars have long ago put the little guy on ignore. I also feel PGNX/SLXP has an excellent shot at FDA label expansion. The would give the first of two big milestones to PGNX, the Sc Relistor label expansion approval ($40 million) and oral formulation approval ($50 million) to give $90 million to PGNX, or about $1.20/share at current stock price.
Ineedmore, I was talking about who gets their product out first for the chronic pain indication. FDA approval of label expansion for sc Relistor would mean they get to market first in the chronic pain indication.
It is a mark of your insecurity and lack of class that you immediately resort to insults when none are warranted. I thought you were confused and attempted to gently set the record straight. You don't need more money, you need more class because you obviously have little to none. I also enjoy when a person such as yourself calls someone an idiot but displays that they are actually an ignorant idiot. It is "you're" an idiot, which is a contraction of the words "you" and "are", not the possessive "your". See, you're an idiot, and I mean that with all sincerity.
By the way, Movantik takes significantly longer to work than Relistor in either the sc or oral formulations.
ineed, you are confused. The sc Relsistor formulation is awaiting the FDA decision for approval. You must be thinking about the oral Relistor formulation.
on target syenfrout. After SNTA gets a few of those hsp90-drug conjugates into trials we might be able to talk about a pipeline.
Dude, there is a major difference between an open label trial and a poorly run one. It is sad if you don't see it.
ca_fisherman, I have had the imbecile jmelink on ignore for quite sometime. Unfortunately, I can still see that he has posted even though the text is hidden so that I don't have to see what gibberish he is posting now.
klaus, you are clueless. It was the data from Entereg that caused concerns about CV issues. Entereg also had an unusual signal with neoplasia development. Relistor had nothing to do with it. You seem to be under the impression (delusion) that it is a new drug. Relistor has been on the market for 6 years and in use for very sick patients. If there were heart issues, it would have already surfaced. The sc Relistor formulation has significant data in a long term, albeit uncontrolled trial. CV events were not an issue. I don't guarantee that the FDA will approve sc Relistor in less than 30 days, but I am betting cash on it.
You comment about the small size of PGNX being a negative further illustrates how clueless you are. See, PGNX has SLXP as a partner. They have deep pockets and extensive experience in GI tract drugs as well a a large sales force with a history of dealing with GI physicians in the US. SLXP is responsible for all the Relistor developmental expenses, but PGNX gets a 15% cut as well as milestones. These milestones are $40 million for sc approval in chronic pain and $50 million for approval of the oral Relistor formulation, which are substantial considering the $300 million PGNX market cap. The oral formulation has a good shot at approval if the sc formulation is approved. However, we need to say what the FDA says regarding sc Relistor, and then what the discussions between the FDA and SLXP regarding the path towards Relistor oral formulation approval.
dcxavier, I know you well and respect you from your comments on the PGNX board. I will take klaus with a grain of salt. I agree that there will likely be a black box warning for patients with CV risks for any mu-opiod receptor drug. We disagree about subcutaneous Relistor getting FDA approval, but hey that is what makes markets. I am on the fence about oral Relistor, but if the FDA grants sc Relistor approval, the path for the oral formulation will be easier than many feel. Many here don't appreciate how much the sc $40 milestone payment means to PGNX as its market cap has just crossed $300 million with the recent rise.
Oh, so you have become a trader now :) . We must both be feeling pretty good about our recent purchases. I liked getting MDVN in the mid- $60s, SGEN in the upper $30s, CELG at $138, ENTA at $34 and recently bought some GILD at $79. I should buy more GILD.
The Barrons article might have given PGNX some traction. What ever it is, you know it pleases me. Let's have another few day of 5% or more stock price increases.
beans, I see you are grasping for anything to try support your argument. This is what you wrote "I'm genuinely surprised there seems to be confusion on this point, clearly enough people understand and are in agreement, and that is why we see NKTR responding positively post adcom and PGNX has effectively stalled out."
Both NKTR and PGNX are up close to 15% since their close before the ADCOM. The recent Barrons disagreed with your assessment by the way. You seem to be looking at oral Relistor as if it is a completely new, different and untreated drug than sub-cutaneous Relistor. The oral Relistor formulation has been tested in a several month long controlled phase III trial, and no obvious safety issues were raised. The safety profile looked as good or better than sub-cutaneous Relistor. I don't know if that will merit FDA approval, but it is a nice step in they direction and you should acknowledge it as such instead of giving it a smug dismissal. If it worries you that much, why not buy a little PGNX to hedge your bets.